KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Lobeglitazone improves glycaemic control as add-on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double-blind, randomised, placebo-controlled trial.

Da Hea Seo, Kyung Wan Min, Ho Sang Sohn, Sang Yong Kim, In-Kyung Jeong, Cheol-Young Park, Kun-Ho Yoon, So Hun Kim, Bong-Soo Cha

Diabetes Obes Metab 28(1) 728-740

PMID41236870
PMCIDPMC12673466
DOI10.1111/dom.70257
发表日期2025-11-14
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:非 KM 图;FIGURE 3:非 KM 图。
摘要

摘要

AIMS: This study aimed to evaluate the efficacy and safety of triple therapy with lobeglitazone 0.5 mg as an add-on treatment compared with placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin. MATERIALS AND METHODS: In this Phase 3, multicentre, double-blind, randomised trial, patients with T2DM who had an insufficient response to metformin (≥1000 mg/day) and empagliflozin 10 mg/day (Study 1) or 25 mg/day (Study 2) were randomised to receive either lobeglitazone 0.5 mg/day, or placebo once daily for 24 weeks. Participants then entered an open-label extension phase for an additional 28 weeks, bringing the total treatment duration to 52 weeks. The primary endpoint was the change from baseline in glycated haemoglobin (HbA1c) at 24 weeks. RESULTS: At 24 weeks, the mean change in HbA1c was significantly greater with lobeglitazone than with placebo, regardless of the background empagliflozin dose (-0.71%; 95% confidence interval, -0.88 to -0.55; p < 0.001 in Study 1 and -0.62%; -0.79 to -0.45; p < 0.001 in Study 2). A higher proportion of patients achieved HbA1c levels <7% with lobeglitazone compared to placebo (48.7% vs. 13.4% in Study 1, and 44.4% vs. 13.0% in Study 2; p < 0.001). Although the incidence of adverse events was numerically different between groups, no statistically significant differences were observed, indicating a generally comparable profile for the triple combination therapy with metformin, empagliflozin, and lobeglitazone. CONCLUSIONS: Lobeglitazone as an add-on to empagliflozin and metformin significantly improved glycaemic control in patients with T2DM inadequately controlled on metformin and empagliflozin dual therapy. The treatment was well tolerated, with a low incidence of adverse events.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Study flowchart for Study 1 (empagliflozin 10 mg + metformin) (A) and Study 2 (empagliflozin 25 mg + metformin) (B).
非 KM Figure
FIGURE 2(A) Changes in glycosylated haemoglobin (HbA1c). (B) Changes in fasting plasma glucose (FPG). (C) Proportions of participants who achieved HbA1c targets of <7% and <6.5% at Week 24 from baseline for Study 1. *<0.05, **<0.01, ***<0.001, footnotes denote statistically significant differences between groups.
非 KM Figure
FIGURE 3(A) Changes in glycosylated haemoglobin (HbA1c). (B) Changes in fasting plasma glucose (FPG). (C) Proportions of participants who achieved HbA1c targets of <7% and <6.5% at Week 24 from baseline for Study 2. *<0.05, **<0.01, ***<0.001, footnotes denote statistically significant differences between groups.
非 KM Figure